Home Guides How to Inject Tirzepatide
How to Inject Tirzepatide: Sites, Technique, and the Mistakes That Waste Medication
Tirzepatide is injected subcutaneously once weekly into the abdomen at least two inches from the navel, the front or outer thigh, or the back of the upper arm. Rotate the site each week. Com…
Tirzepatide is injected subcutaneously once weekly into the abdomen at least two inches from the navel, the front or outer thigh, or the back of the upper arm. Rotate the site each week. Compounded tirzepatide usually arrives as a vial and syringe rather than a pen, which adds a drawing-up step.
Choosing and rotating sites
All three sites are equivalent for absorption. Rotating matters because repeated injection into the same spot causes lipohypertrophy — thickened tissue that absorbs unpredictably. A simple system is to move clockwise around four abdominal quadrants, then switch to thighs for a cycle.
Stay at least two inches from the navel and avoid scars, moles and any area that is bruised or tender.
Vial and syringe technique
Let the vial come to room temperature for about 15–30 minutes — cold medication stings more. Wipe the stopper with alcohol and let it dry. Draw air equal to your dose into the syringe, inject it into the vial, invert and withdraw your prescribed volume, then tap out air bubbles.
The most common and most expensive mistake is misreading units. Compounded vials come in varying concentrations, so the same milligram dose can be a different volume between refills. Re-read your label every single time a new vial arrives, and confirm the volume with your prescriber if the number changed.
Making it nearly painless
Room-temperature medication, a dry alcohol swab, a quick 90-degree insertion and a slow steady push. Pinching a fold of skin helps on the abdomen. Do not massage the site afterwards.
Storage
Refrigerate at 36–46°F. Do not freeze, and do not use medication that has frozen. Compounded tirzepatide is commonly dated for a 28-day beyond-use window once dispensed; some pharmacies extend it with stability testing. The vial label governs — not a general rule you read online.
Common questions
How much does tirzepatide cost per month without insurance?
Compounded tirzepatide from licensed US telehealth programs runs roughly $99 to $299 per month depending on the provider and whether the price is flat or scales with your dose. Brand-name Zepbound through LillyDirect self-pay runs about $299 to $449 per month depending on strength. Retail Zepbound without any program is around $1,089.
Is compounded tirzepatide the same as Zepbound?
The active ingredient is the same molecule. Zepbound is FDA-approved, manufactured by Eli Lilly and reviewed by FDA for safety, effectiveness and quality. Compounded tirzepatide is prepared by a state-licensed pharmacy for an individual patient and is not FDA-approved or FDA-reviewed. The pharmacology is identical; the quality assurance structure is not.
How much weight will I lose on tirzepatide?
In SURMOUNT-1, mean 72-week weight loss was 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, versus 3.1% on placebo. If you have type 2 diabetes, expect roughly two-thirds of those figures based on SURMOUNT-2. Real-world averages run lower than trial averages, mostly because people stop early.
Is tirzepatide better than semaglutide?
For weight loss, yes, on the available randomized evidence. SURMOUNT-5 compared them head-to-head over 72 weeks and found 20.2% mean loss on tirzepatide versus 13.7% on semaglutide. Semaglutide retains a stronger cardiovascular outcomes label from the SELECT trial and is cheaper in compounded form.
People also ask about tirzepatide injection guide
What is tirzepatide injection guide?
Tirzepatide injection guide is covered in full on this page, with the clinical detail drawn from the tirzepatide prescribing information and the published SURMOUNT and SURPASS trial program, and any price figures drawn from our tracked dataset and dated to their last verification.
Does tirzepatide injection guide apply to compounded tirzepatide as well as Zepbound?
The molecule is the same, so the clinical content applies to both. What differs is regulatory status, dose metering and price: compounded preparations are not FDA-approved, arrive as a multi-dose vial you measure yourself, and cost a fraction of the brand routes.
How much does tirzepatide injection guide cost per month in 2026?
Compounded tirzepatide runs from $133 per month at the entry dose across the 21 compounded programs we track. At a 10 mg maintenance dose the cheapest tracked route is Oak Longevity at $199 per month, or about $2,388 for a first year on the standard escalation. Brand Zepbound through manufacturer self-pay sits well above that and pharmacy retail well above again. Verified 2026-08-05.
Is tirzepatide injection guide FDA-approved?
Brand tirzepatide (Zepbound and Mounjaro) is FDA-approved. Compounded tirzepatide is not: FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before they are marketed. The active molecule is the same; the regulatory review is not.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.